1 / 3
| Item | Specification |
|---|---|
| Product Name | Tirzepatide |
| CAS NO. | 2023788-19-2 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4,813.45 g/mol |
| Amino Acid Sequence | 39-amino acid peptide with C18 diacid moiety |
| Purity (RP-HPLC) | ≥ 98.5% (UV detection at 214 nm) |
| Solubility | Soluble in water, phosphate-buffered saline |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Dual GIP and GLP-1 receptor agonist with potent glucose-dependent insulin secretion properties |
| Storage Conditions | Store at -20°C or below in dry, light-protected conditions |
| Packaging | Available in vials of 10mg, 50mg, 100mg, and bulk custom quantities. |
| Stock Location | Stock in USA |
| MOQ | 10mg for standard sizes. Custom synthesis projects welcome. |
Tirzepatide activates both the GIP and GLP-1 receptors, which are natural incretin hormone receptors involved in blood sugar regulation. The dual agonism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and directly reduces appetite and food intake in the brain. The GIP component is believed to potentiate the effects of GLP-1, leading to greater efficacy in reducing body weight and improving insulin sensitivity.
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) who have at least one weight-related comorbidity, such as hypertension, dyslipidemia, or cardiovascular disease.
In the landmark SURPASS clinical trial program for diabetes, Tirzepatide demonstrated significantly greater reductions in HbA1c (up to -2.58%) compared to semaglutide and other comparators. In the SURMOUNT trials for obesity, it achieved mean weight reductions of up to 22.5% (approximately 52 lbs or 24 kg) at the highest dose over 72 weeks, establishing a new benchmark for non-surgical weight loss agents.
GlobalTech Co., Ltd. is committed to providing high-purity biotechnological peptide products, adhering strictly to quality standards and obtaining internationally recognized certifications.
Our production partners all employ GMP-compliant production systems and possess standardized quality control processes covering raw material procurement, synthesis, purification, testing, packaging, and storage. Each batch of product comes with complete documentation, including a Certificate of Analysis (COA), HPLC purity report, mass spectrometry (MS) chromatograms, and third-party testing reports available upon request.
Our commitment to quality, transparency, and regulatory compliance ensures the provision of reliable, stable, and research-grade peptide products to our global partners.
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation. We can also customize packaging according to customer needs.
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
Global Technology Co., Ltd. is a modern and advanced enterprise specializing in the production and export of active pharmaceutical ingredients (APIs), peptides, and plant extracts. The company invests in and collaborates closely with domestic manufacturers holding GMP, DMF, and FDA certifications, as well as laboratories at renowned universities, to meet diverse customer needs ranging from gram-level to ton-level. This enables Dejurui Pharmaceutical to provide customers with more flexible and convenient access to cost-effective, high-quality products and superior services.
We focus on the research and development and supply of high-quality chemical products, strictly adhering to international standards and quality systems. Our products are stable in performance and reliable in purity, widely used in industrial manufacturing, scientific research, and the fine chemical industry. We provide solid support at every stage with a professional and responsible attitude.
Tirzepatide is a novel therapeutic agent used primarily to improve glycemic control in adults with type 2 diabetes mellitus (as an adjunct to diet and exercise) and for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight conditions (BMI ≥27 kg/m²) accompanied by weight-related comorbidities. Administered as a once-weekly injection, it significantly reduces body weight, enhances insulin sensitivity, and improves overall metabolic parameters.
Tirzepatide acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) incretin receptor agonist. By stimulating pancreatic beta cells to produce insulin in a glucose-dependent manner and suppressing glucagon release, it reduces liver glucose production and lowers postprandial glucose spikes. Furthermore, it slows gastric emptying and stimulates CNS receptors responsible for promoting satiety and appetite control.
Because Tirzepatide delays gastric emptying, it can alter the absorption kinetics of concomitant oral medications, particularly those requiring quick onset or possessing narrow therapeutic ranges (such as Warfarin or Levothyroxine). In addition, when co-administered with insulin or insulin secretagogues like Glipizide, an increased risk of hypoglycemia can occur, requiring dosage adjustments. Gastrointestinal symptoms and reduced overall food intake may also affect nutritional and drug absorption profiles.
In clinical evaluation programs, Tirzepatide demonstrated substantial clinical benefits. During the SURPASS trials for diabetes, it lowered HbA1c levels by up to -2.58%, outperforming active comparators such as semaglutide. In the SURMOUNT obesity trials, participants achieved an average reduction in body weight of up to 22.5% (approx. 52 lbs or 24 kg) over a 72-week treatment duration at maximum dose.
Tirzepatide is supplied as a high-purity (≥98.5% RP-HPLC) white to off-white lyophilized powder. It must be stored at -20°C or lower under dry, light-protected conditions to preserve peptide integrity and biological activity. Endotoxin levels are maintained below 1.0 EU/mg, and product documentation includes comprehensive analytical testing (COA, HPLC, and MS).
Product quantities are available in standard vials of 10mg, 50mg, 100mg, as well as bulk and custom synthesis quantities with stock availability in the USA. Shipments are packed using specialized protective solutions and dispatched via international air freight carriers including DHL, FedEx, UPS, and TNT to provide reliable, fast transit while protecting the product from adverse environmental exposure.
